Litcius/Paper detail

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Michael Wang, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian W. Flinn, Benoît Tessoulin, Alvaro J. Alencar, Shuo Ma, Ewa Lech‐Marańda, Joanna Rhodes, Krish Patel, Jennifer A. Woyach, Nicole Lamanna, Yucai Wang, Constantine S. Tam, John F. Seymour, Talha Munir, Hirokazu Nagai, Francisco J. Hernandez‐Ilizaliturri, Anita J. Kumar, Andrew D. Zelenetz, Preetesh Jain, Binoj C. Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato

2022Blood25 citationsDOI

Topics & Concepts

Mantle cell lymphomaBruton's tyrosine kinaseIbrutinibRefractory (planetary science)MedicinePhases of clinical researchLymphomaInternal medicineOncologyChronic lymphocytic leukemiaClinical trialMaterials scienceLeukemiaComposite materialReceptorTyrosine kinaseChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentViral-associated cancers and disorders
Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study | Litcius